NeuroTherapia
Private Company
Total funding raised: $1.5M
Overview
NeuroTherapia is a private, clinical-stage biotech advancing an oral, small molecule CB2 receptor agonist, NTRX-07, to treat neuroinflammatory conditions like Alzheimer's Disease (AD) and neuropathic pain. The company, a Cleveland Clinic spin-out founded in 2009, has completed Phase 1 studies showing safety and a trend toward cognitive improvement in AD, with a Phase 2 trial planned for 2024. NeuroTherapia is backed by venture capital, foundations, and state grants, positioning it to explore a novel anti-inflammatory mechanism that could complement existing protein-targeting therapies in the challenging CNS market.
Technology Platform
Oral small molecule cannabinoid type 2 (CB2) receptor agonists that modulate microglia to reduce neuroinflammation.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
NeuroTherapia competes in the crowded Alzheimer's and neuropathic pain markets, but its specific focus on oral CB2 agonism for neuroinflammation is a differentiating niche. It faces competition from other anti-inflammatory approaches and large pharma companies with amyloid-targeting antibodies, but its mechanism offers a potential complementary pathway rather than a direct head-to-head challenge.